School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia.
J Antimicrob Chemother. 2018 Jun 1;73(6):1647-1650. doi: 10.1093/jac/dky057.
Piperacillin is a β-lactam penicillin antibiotic commonly used for the empirical therapy of sepsis and other hospital-acquired infections. However, knowledge regarding the effect of sustained low-efficiency diafiltration (SLED-f), a technique increasingly being used in ICUs, on piperacillin pharmacokinetics (PK) and dosing in critically ill patients is lacking.
To describe the PK of piperacillin during SLED-f and compare the results with those reported for other forms of renal replacement therapies.
Serial blood samples were collected at pre- and post-filter ports within the SLED-f circuit during SLED-f in one session and from an arterial catheter during sampling without SLED-f. Piperacillin concentrations were measured using a validated chromatography method. Non-compartmental PK analysis of the data was performed.
The median clearance and area under the concentration-time curve during SLED-f were 6 L/h and 532 mg·h/L, respectively. Fifty-eight percent of piperacillin was cleared by a single SLED-f session (6 h) compared with previous reports of 30%-45% clearance by a 3.5 h intermittent haemodialysis session. Clearance, half-life and area under the concentration-time curve during SLED-f obtained from this study were comparable with those reported in the post-dilution mode of continuous veno-venous haemodiafiltration studies.
As it can be challenging to accurately predict when SLED-f will be initiated in the critically ill, a maintenance dose of at least 4 g every 12 h with at least a 2 g replacement dose post-SLED-f would be a practical approach to piperacillin dosing in ICU patients with anuria receiving SLED-f with a duration similar to the current study.
哌拉西林是一种β-内酰胺青霉素类抗生素,常用于脓毒症和其他医院获得性感染的经验性治疗。然而,关于持续低效率透析滤过(SLED-f)对重症患者哌拉西林药代动力学(PK)和剂量的影响的知识还很缺乏,SLED-f 是一种在 ICU 中越来越多使用的技术。
描述 SLED-f 过程中哌拉西林的 PK,并将结果与其他形式的肾脏替代疗法的报告进行比较。
在一次 SLED-f 过程中,在 SLED-f 回路的预过滤器和过滤器端口收集血液样本,并在没有 SLED-f 的情况下从动脉导管中收集样本。使用验证后的色谱法测量哌拉西林的浓度。对数据进行非房室 PK 分析。
SLED-f 期间的中位清除率和浓度-时间曲线下面积分别为 6 L/h 和 532 mg·h/L。与先前报告的 3.5 小时间歇性血液透析清除率为 30%-45%相比,单次 SLED-f 清除了 58%的哌拉西林。本研究中获得的 SLED-f 期间的清除率、半衰期和浓度-时间曲线下面积与连续静脉-静脉血液滤过研究的后稀释模式报告的结果相当。
由于在重症患者中准确预测何时开始 SLED-f 具有挑战性,因此对于接受 SLED-f 且持续时间与本研究相似的无尿 ICU 患者,在 SLED-f 后至少每 12 小时给予至少 4 g 的维持剂量和至少 2 g 的补充剂量,可能是哌拉西林剂量的一种实用方法。